Developent of glycolipid vaccines against tuberculos is

致病性分枝杆菌利用宿主来源的葡萄糖生物合成的葡萄糖单菌酸在豚鼠中被测试了其诱导特异性T细胞反应的能力。这是第一次表明糖脂类能够在致敏动物中引起延迟型超敏反应。此外，单菌糖诱导的T细胞反应高度偏向于保护性th1型细胞因子的产生。因此，这些结果强调了单菌酸葡萄糖可能作为一种新型抗结核疫苗的可能性。

Glucose monomycolate that pathogenic mycobacteria biosynthesize by utilizing host-derived glucose was tested for its ability to induce specific T cell responses in guinea pigs. It was shown for the first time that the glycolipid species was capable of eliciting delayed-type hypersensitivity in sensitized animals. Furthermore, the glucose monomycolate-induced T cell response was highly skewed to the production of the protective TH1-type cytokines. Thus, these results underscored the possibility that glucose monomycolate could function as a novel type of anti-tuberculosis vaccines.